ZoBio is the established, market leading innovator of an array of biophysical
techniques to support modern drug discovery efforts.
In its 9 years of existence, ZoBio has integrated modern drug discovery technologies into an
efficient pipeline, to support hit to lead programs on targets that no other CRO can address.
 |
|
Starting with our proprietary Target Immobilized NMR Screening (TINS) technology, which has been used in over 60 projects to deliver highly validated fragment ligands for a wide array of challenging targets. ZoBio is developing industry leading, innovative techniques to support FBDD, including novel NMR methods to rapidly elucidate the structure of target-ligand complexes. Computational chemistry methods are integrated with our exclusive NMR techniques to steer hit-to-lead optimization and enable rapid progression of fragment hits into potent and ligand-efficient lead compounds.
Combined with ZoBio's in-house protein production, orthogonal validation methods, such as SPR and biochemical assays, X-ray crystallography and direct access to exclusive synthetic chemistry, ZoBio possesses all the tools to support Fragment Based Drug Discovery programs, from gene to lead.
|
| For a complete list of research services click here. |
|
|
